Additionally, there is a notable increase in mTOR pathway activity in high-risk MDS patients, with rapamycin showing potential therapeutic effects, suggesting the therapeutic potential of targeting the PI3K/Akt/mTOR network in both AML and high-risk MDS cases [45]. This evidence concerns the gene AKT1 and acute myeloid leukemia.